This Title All WIREs
How to cite this WIREs title:
WIREs Nanomed Nanobiotechnol
Impact Factor: 7.689

Nanotherapeutics for multiple myeloma

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

Multiple myeloma (MM) is an age‐related hematological malignancy with an estimated 30,000 new cases and 13,000 deaths per year. A disease of antibody‐secreting malignant plasma B‐cells that grow primarily in the bone marrow (BM), MM causes debilitating fractures, anemia, renal failure, and hypercalcemia. In addition to the abnormal genetic profile of MM cells, the permissive BM microenvironment (BMM) supports MM pathogenesis. Although advances in treatment options have significantly enhanced survival in MM patients, transient perfusion of small‐molecule drugs in the BM does not provide sufficient residence to enhance MM cell–drug interaction, thus allowing some myeloma cells to escape the first line of treatment. As such, there remains a crucial need to develop advanced drug delivery systems that can navigate the complex BMM and effectively reach the myeloma cells. The high vascular density and spongy nature of bone structure suggest that nanoparticles (NPs) can serve as smart drug‐delivery systems capable of extravasation and retention in various BM compartments to exert a durable therapeutic effect. In this focus article, we first summarize the pathophysiology of MM, emphasizing how the BM niche presents serious challenges for effective treatment of MM with small‐molecule drugs. We then pivot to current efforts to develop NP‐based drug carriers and intrinsically therapeutic nanotherapeutics. The article concludes with a brief perspective on the opportunities and challenges in developing and translating nanotherapeutics to improve the treatment outcomes of MM patients. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Schematic representation of bone marrow niches and cell types comprising the stroma
[ Normal View | Magnified View ]
Various nanoparticle platforms that can be utilized for targeting multiple myeloma in vivo
[ Normal View | Magnified View ]
Advantages of nanoparticles over the use of small‐molecule drugs such as peptides or biologics
[ Normal View | Magnified View ]

Browse by Topic

Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts